DXCM monthly performance report
Monthly DXCM research: returns, drawdown, relative strength, seasonality, and key stats.
DXCM monthly report
—
Key takeaways
- Dexcom (DXCM) closed August 2026 at $83.02, down 0.52% for the month and +8.66% over the trailing 12 months.
- Year-to-date, DXCM is +25.09%, outperforming the S&P 500 which has returned +12.71% YTD.
- The stock is trading +22.07% versus its 200-day moving average ($68.01), a bullish technical signal.
- Over the past three years, DXCM has underperformed the S&P 500 by −103.02%, with a relative strength index reading of 40.2.
- Win rate over the trailing 39 months stands at 46.2% — 18 positive months versus 21 negative months.
Dexcom ended August 2026 at $83.02, posting a monthly return of −0.52%. The S&P 500 returned +2.88% over the same window, leaving relative performance at −3.40%.
The current quarter stands at +16.64% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +22.07% versus the 200-day moving average ($68.01).
Year-to-date, DXCM is +25.09% against SPY +12.71%, a gap of +12.38%. The stock is currently −5.47% below its 52-week high, with maximum 3-year drawdown at −60.95%.
| Period | DXCM | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.44% | −0.16% | +0.60% |
| 1 Week | +10.49% | +5.36% | +5.13% |
| 1 Month | −0.52% | +2.88% | −3.40% |
| 3 Months | +35.32% | +6.65% | +28.67% |
| 6 Months |